In this episode, Dustin Portela, DO, discusses how treating warts can be a challenge and explores the effectiveness of Swift microwave therapy. The episode reviews how this innovative approach compares to traditional methods and helps patients achieve lasting results.
An expert discusses how treatment for alopecia areata begins with topical/intralesional therapies for limited disease and progresses to systemic options for extensive involvement or treatment resistance. Treatment decisions are guided by disease severity, patient age, comorbidities, and treatment goals. FDA-approved systemic agents include ritlecitinib (JAK3/TEC inhibitor) and baricitinib (JAK1/2 inhibitor), which block inflammatory pathways to promote hair regrowth with favorable efficacy, though they require monitoring for potential adverse effects.
An expert discusses how alopecia areata affects approximately 2% of the population globally, with onset typically in childhood or early adulthood. Patients often present with autoimmune comorbidities (thyroid disorders, vitiligo, atopic dermatitis) and psychological distress. Diagnostic challenges include differentiating from other hair loss conditions and predicting disease course. Treatment difficulties involve unpredictable responses, lack of standardized protocols, and addressing both physical symptoms and psychological impact.
Panelists discuss the systemic treatment option tralokinumab for pediatric atopic dermatitis (AD), focusing on its mechanism of action, efficacy, safety, and role in improving outcomes for children with moderate to severe disease.
Panelists discuss the topical treatment option tapinarof for pediatric atopic dermatitis, examining its mechanism of action, efficacy, safety, and potential to improve management of the condition in children.
Panelists discuss how physicians can achieve optimal atopic dermatitis management by following American Academy of Dermatology (AAD) guidelines for systemic therapy selection while considering individual patient factors and treatment goals.
Panelists discuss how clinicians can evaluate the severity of atopic dermatitis through comprehensive assessment of symptoms, quality-of-life impact, and treatment response to guide decisions about transitioning patients to systemic therapy.
Independent pharmacies are closing at high rates, leaving many communities without essential health care access.
The panelist discusses how to optimize topical therapy selection and application strategies for a young man with mild atopic dermatitis to achieve symptom control and maintain skin barrier function.
The panelist discusses how to effectively communicate the benefits and potential adverse effects of dupilumab treatment to patients and their families to support informed decision-making.
Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.
Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.
Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.
Well Revolution’s partnership with City Chemist highlights how telehealth can sustain small businesses and improve patient care.
Professor Diamant Thaçi, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumab’s rapid efficacy in treating atopic dermatitis and prurigo nodularis.
This collective initiative gives Mindy Haws, MD, and her team the ability to reach more women in a way that gives back and helps them succeed.
Mindy Haws, MD, spoke to Dermatology Times about the new videos, podcasts, and other resources LIMITLESS offers for women at all stages of their careers.
Panelists discuss the topical treatment option roflumilast for pediatric atopic dermatitis, exploring its mechanism of action, efficacy, safety, and potential role in managing the condition.
The panelist discusses how systemic atopic dermatitis therapies now emphasize targeted biologics and Janus kinase inhibitors, requiring personalized approaches, comprehensive monitoring, and holistic patient management.
The panelist discusses how a 28-year-old woman with moderate atopic dermatitis requires personalized, comprehensive management addressing hand involvement, corticosteroid concerns, and potential Janus kinase (JAK) inhibitor therapy, focusing on symptom relief, safety, and patient-specific factors.
Panelists discuss the latest advances in topical treatments for pediatric atopic dermatitis, covering newly available options and those on the horizon with a focus on their mechanisms of action, efficacy, and safety profiles.
The panelist discusses how to evaluate and select appropriate therapeutic options for a 10-year-old girl while considering factors such as safety, efficacy, and treatment adherence.
The panelist discusses how understanding the diverse manifestations of atopic dermatitis enables health care providers to develop personalized treatment approaches for optimal patient outcomes.
The co-founder of PathAI and its PathAssist Derm tool believes AI is going to be incredibly valuable for dermatologists and dermatopathologists.
Merz Aesthetics' global study reveals that aesthetic treatments boost self-confidence, social well-being, and self-perception beyond physical appearance.
Although the tool is currently designed for research use only, CEO Andy Beck, MD, PhD, is excited about its future in clinical dermatopathology.
Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.
“I think some key things that stand out to me are that it's safe, effective, backed by rigorous clinical data, and has very high patient satisfaction,” Watchmaker said about the new product.
The overwhelmingly positive feedback from both clinicians and patients reinforces the unmet need roflumilast foam is addressing in seborrheic dermatitis care.
Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.
